Compare Expensify Inc (EXFY) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Intuitive Surgical, Inc. — how do they compare? Expensify Inc trades at $1.8 (market cap $170.21M), while Intuitive Surgical, Inc. trades at $355.5 (market cap $137.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 809.4× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| EXFY | ISRG | |
|---|---|---|
Market Cap | $170.21M | $137.76B |
Sector | Technology | Health |
52-Week High | $2.33 | $592.85 |
52-Week Low | $0.75 | $379.50 |
Enterprise Value | $109.24M | $133.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.77, down 2.21% on the day, with a bullish technical signal from moving averages but mixed earnings history. Revenue for 2025 was $142.10M, but the company posted a net loss of -$21.39M, with negative profit margins and ROE. Recent news highlights product innovations like AI-powered expense automation and a $25M stock buyback program, indicating active management efforts to drive growth and shareholder value.
The outlook remains challenging due to persistent unprofitability, though positive cash flow from operations and strategic partnerships offer some stability. Investment opportunities hinge on successful execution of new AI and travel billing initiatives to improve margins. Key risks include intense competition in expense management software and the company's ability to achieve sustained profitability amid fluctuating revenues.
Intuitive Surgical (ISRG) trades at $399.75, up 5.34% today, but remains 25% below its 52-week high amid 2026 weakness. The stock shows bearish technical signals with key resistance near $402, while fundamentals remain strong with consistent revenue growth to $10.06B in 2025 and a 28.15% net margin. Recent quarters have seen earnings beats, with Q2 2026 results due July 16. Analyst sentiment is predominantly bullish with a $552.36 price target, though competition concerns persist.
Outlook: Long-term growth prospects in robotic surgery are compelling, supported by da Vinci 5 adoption and AI integration. Near-term risks include margin pressure and competitive threats. The stock offers potential upside if Q2 earnings beat expectations, but volatility may continue until growth catalysts materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
